Our priority is to preserve the health of people and our planet.
.
- RVP-001: the gadolinium-free general purpose MRI contrast agent.
- RVP-001 is in Phase 2 clinical studies, with FDA Fast Track designation.
All current MRI contrast agents cause accumulation of the rare earth element gadolinium in the brain and body of every patient. Gadolinium from MRI agents results in rising pollution of earth's surface waters, and the global gadolinium supply chain is controlled by China, creating a key vulnerability for vital healthcare systems.
Despite decades of growing concern this has remained an exceptionally difficult scientific problem: until now there have been no viable alternatives to fully replace existing MRI agents. RVP-001, designed to be a direct replacement for current standard of care MRI contrast agents, is based on manganese, a biocompatible element essential for life. Our contrast agent promises substantial benefits for patients, medicine, and society, and the potential to transform a growing global market of 65 million doses per year. - Reveal's pipeline: ground-breaking fibrogenesis imaging agents.
- Building on research by Reveal's co-founder, Professor Peter Caravan (Harvard Medical School & Massachusetts General Hospital), Reveal is developing first in class fibrogenesis imaging agents. These agents are designed to identify active fibrotic disease and have potential applications for diagnosis, staging, patient stratification, and monitoring response to treatment in a wide range of fibrotic diseases.
Team
- Vera Hoffman - CEO
- Vera has led Reveal since inception and is Principal Investigator of Reveal's >$17M in grants from the National Institutes of Health and other organizations. Previously, Vera directed startups and high growth enterprises from idea stage through global scale. She guided the design, development, and commercialization of over a dozen innovative technology-based products; led teams across six continents to identify, plan, and execute new business opportunities for a large global enterprise; and developed the initial business plan for Acquia ($1B exit, 2019). Vera has degrees in Chemistry and Mathematics, and an MBA from Harvard Business School.
- Peter Caravan - Co-Founder
- Peter is a world leader in MRI contrast agent development and applications. He leads a molecular imaging lab at Massachusetts General Hospital (MGH) focused on contrast agents and molecular probes to image fibrosis and thrombosis, as well as alternatives to GBCAs; Peter is a co-inventor of RVP-001. At MGH he invented two novel molecular tracers and he holds INDs for their ongoing clinical development. In industry Peter was part of the team that developed the FDA-approved blood pool agent Ablavar® (Gadofosveset), and was co-inventor of the thrombus-specific agent EP-2104R, the first molecular MR imaging probe to enter human clinical trials. Peter is a Fellow of the International Society for Magnetic Resonance in Medicine (ISMRM), a Fellow of the World Molecular Imaging Society (MWMIS), and was awarded the 2019 Torsten Almén Award for Pioneering in Contrast Media Research.
- Tom Grist - Medical
- Tom is a trailblazer in MRI: he is focused on strategy, sustainability, and “bench to biosphere” for global radiology, and spearheads the medical domain for Reveal. After his first degree in bioengineering Tom worked on nascent MRI technology, followed by his medical career and groundbreaking work in cardiovascular MRI and MRA. He led Radiology at UW for almost two decades and has contributed to a dozen contrast agent studies from Phase 1 through 3. Tom is President of the International Society for Strategic Studies in Radiology (IS3R), a 2025 Radiological Society of North America (RSNA) Gold Medal winner, past president of the International Society of Magnetic Resonance in Medicine (ISMRM) and the Society of Chairs of Academic Radiology Departments (SCARD), and has been honored as a Fellow of the American Heart Association (AHA), ISMRM, the American Institute for Medical and Biological Engineering (AIMBE), the Society for Advanced Body Imaging (SABI), and the American College of Radiology (ACR).
- Susan Stewart - Regulatory Affairs
- Sue is an expert in biopharmaceutical regulatory affairs: devising innovative strategies for novel drugs, overseeing regulatory submissions across all stages of product development, and leading interactions with global health authorities. Sue served in senior regulatory roles at Frequency Therapeutics, Candel Therapeutics, Kaleido Biosciences, Tokai Pharmaceuticals, Transmolecular, Inc, and Genzyme Corporation. Sue has a J.D. and is a Fellow (FRAPS) of the Regulatory Affairs Professionals Society, a Director of the Society’s Board, and holds Regulatory Affairs Certifications (RAC) for both the US and Europe.
- John Amedio - Chemistry, Manufacturing, & Controls
- John is an expert in technical and regulatory CMC development strategy, and has worked with Reveal since the company's first technology transfer. John has delivered profitable and patented pre-clinical through commercial manufacturing processes for drugs including Ablavar®, Arbaclofen, Zinapar™, Zibulin™, Zymafos™, Favipiravir, and multiple NCE’s including peptides and metal-based drugs. John has authored and reviewed CMC sections for numerous regulatory filings (INDs, IMPDs, Amendments, Annual Updates, and NDAs). John earned a PhD in organic chemistry from the University of Delaware.
- Thomas Steele - Nonclinical Pharmacology & Toxicology
- Tom is an expert in pharmacology and toxicology, with extensive experience in preclinical development and toxicology of novel small molecule and biological therapeutics in multiple therapeutic areas. Tom has extensive experience in the drug discovery and development process, as well as regulatory document preparation, review, and submission. He had a vital role in multiple successful “first in human” regulatory applications and served as preclinical expert for two initial marketed product approvals. Tom has held positions at the FDA, large pharmaceutical companies (Roche, Eli Lilly) and small biopharma (Ariad). Tom has a PhD in Pharmacology and Toxicology from Purdue University.
- Eric Gale - Co-Founder
- Eric applies chemistry to solve unmet challenges in radiology and biomedical imaging. He is co-inventor of RVP-001 and was instrumental in the discovery of this contrast agent and its preclinical characterization and synthesis. Eric leads a research laboratory at Massachusetts General Hospital focused on developing transition metal complexes as MRI contrast agents, and is a 2023 Blavatnik Therapeutics Challenge awardee. He has a PhD from the University of Georgia and was a NIH-funded Ruth L. Kirschstein National Research Service Award Scholar.
Reveal's work is supported by over $17M in grants from three institutes of the National Institutes of Health, Massachusetts agencies, and accelerators. Our investors include physicians, patients, and industry experts.
